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Rote of thrombospondin in mesangial cell growth: Possible existence of
an autocrine feedback growth circuit. Thrombospondin (TSP) is an
extracellular matrix glycoprotein involved in mesangial cell (MC) adhesive
and migratory function. We have studied the role of TSP in activation and
proliferation of rat MC in serum-free media. TSP, in a concentration
dependent manner (5 to 20 j.rg/ml), caused an increase in thymidine
uptake, first detectable at 28 hours and more prominent at 48 hours. This
effect was inhibited by heparin and heparan sulfate. TSP induced epider-
ma! growth factor (EGF) secretion and significantly augmented constitu-
tive platelet-derived growth factor-AB (PDGF-AB) secretion by MC in a
concentration dependent fashion. It did not, however, induce TGF-j3,
IL-i, IL-6, IL-8, or TNF-is production. TSP had an additive effect with
exogenous EGF and PDGF on thymidine uptake. Anti-PDGF neutraliz-
ing antibody eliminated the effect of TSP on MC growth. MC displayed a
single class of heparin-inhibitable TSP binding sites (Bma,, 3.8 1.8 x
106/cell, Kd = 80 29 nu). Based on these observations, we propose the
existence of an autocrine positive feedback ioop of MC proliferation
involving TSP and growth factors, and regulated by heparan sulfate.
A common feature of many glomerulopathies is proliferation of
mesangial cells and expansion of mesangial matrix [1, 2]. The
mesangial cells have mixed features of a smooth muscle-like
contractile cell, a fibroblast-like cell able to produce extracellular
matrix components, and of a weak phagocytic cell that under
appropriate stimuli can be activated and participate in inflamma-
tory processes [2—5]. Most of the information on mesangial cell
function is based on in vitro studies. Whereas the applicability of
in vitro data to the in vivo behavior of these cells has been
questioned, it seems that the mesangial cells in various disease
states acquire an activated phenotype which more closely resem-
bles their behavior in culture [6, 7].
The in vitro proliferative and matrix-synthetic responses of
mesangial cells are under the control of a multitude of factors;
prominent among them are growth factors such as platelet-
derived growth factor (PDGF) [8] and transforming growth
factor-beta (TGF-3) [9]. Components of extracellular matrix can
also profoundly modify the proliferative potential of these cells, as
demonstrated by culture of the cells in various matrices [10], and
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by the antiproliferative effect of heparan sulfate on mesangial cells
[11]. Additionally, vasoactive agents, such as angiotensin II, can
stimulate mesangial cell proliferation at concentrations higher
than those needed for their contractile effect [12, 13].
A group of extracellular proteins known as modulators of
cell-matrix interactions is also important in the regulation of
mesangial cell behavior. Best known among them are osteonectin
(or SPARC), tenascin, and thrombospondin [14]. These proteins
seem to regulate detachment-reattachment between cells and the
matrix that surrounds them, a process necessary for cellular
adhesion/migration, and a prerequisite for cell proliferation.
Thrombospondin (TSP) was initially recognized as a compo-
nent of platelets released in response to thrombin [15]. TSP is a
homotrimeric glycoprotein of 450,000 Da molecular weight,
whose subunits are bound together with disulfide bonds. Each
chain has a heparin-binding domain at its N-terminal, followed by
a segment with close homology to type I procollagen, multiple
properdin-like repeats, EGF-like repeats, and Ca k-binding re-
peats (with RGD sequences), ending at the C-terminal, which
binds to platelets and other cell types [16, 17]. The currently
known four isoforms are characterized as TSP ito 4 [16, 18]. The
TSP isolated from platelets seems to be exclusively TSP 1 [16].
TSP is necessary for platelet aggregation [14] and is chemotac-
tic for polymorphonuclear cells [19]. It is produced by macro-
phages, binds to them, and is necessary for recognition and
subsequent phagocytosis of senescent neutrophils by maerophages
[20]. It is also produced by a variety of normal and transformed
cells [14]. TSP inhibits proliferation of endothelial cells [21],
whereas it stimulates proliferation of vascular smooth muscle cells
[22], an effect synergistically enhanced by epidermal growth factor
(EGF) and inhibited by heparin. In smooth muscle cells synthesis
of TSP is induced by PDGF [23].
TSP is synthesized by mesangial cells [24] and transcription of
its mRNA is stimulated by PDGF [25]. It induces mesangial cell
adhesion and migration [26].
In this study, we have investigated the effects of TSP on
mesangial cell growth. We report that TSP increases DNA syn-
thesis by mesangial cells, an effect most likely mediated through
its ability to induce production of PDGF and EGF by these cells;
this creates a positive feedback autocrine system of mesangial cell
growth, which is under the tonic inhibitory effect of heparan
sulfate.
350
Marinides et a!: Thrombospondin in mesangial cell growth 351
Methods
Source of materials
Sprague-Dawley rats were purchased from Harlan (Indianapo-
lis, Indiana, USA). Animal use and care were in compliance with
NIH guidelines. Cell culture supplies (media, serum, supple-
ments) were from Gibco/BRL (Grand Island, New York, USA).
Human recombinant PDGF BB and epidermal growth factor
(EGF) were purchased from Gibco/BRL (Gaithersburg, Mary-
land, USA), and heparin was from Sigma (St. Louis, Missouri,
USA). Tritiated thymidine (3H-TdR) was obtained from Dupont-
New England Nuclear (Boston, Massachusetts, USA). Anti-hu-
man PDGF neutralizing antibody was from Collaborative Re-
search (Bedford, Massachusetts, USA). This polyclonal antibody
is able to neutralize the biologic activity of all three PDGF
isomers from various mammalian species including the rat. We
used QuantikineT ELISA kits from R&D Systems (Minneapolis,
Minnesota, USA) for PDGF AB, EGF, TGF-13, IL-113, IL-6, IL-8,
and TNF-a. Antibodies for myosin, desmin, alpha-smooth muscle
actin, factor VIII, and for macrophage marker ED-i, as well as an
LDH assay kit were from Sigma. Antibody for rat Thy-i was
obtained from Bioproducts for Science (Indianapolis, Indiana,
USA), and goat anti-mouse IgG antibody was from Meloy Inc.
(Springfield, Virginia, USA).
Heparan sulfate was a gift from Drs. A. Linker and P. Hovingh
(Univ. of Utah, Salt Lake City, Utah, USA) and its characteristics
have been described [111. Briefly, it is isolated from bovine lung
and fractionated by chromatography on Bio-Rad AG 1 X 8 resin
and elution with NaCl in a stepwise fashion. Material eluted by
1.3 M NaCI was used here; this fraction has a molecular weight of
—11,000 and contains 13% sulfate, 3.9% N-acetyl, and 48%
uronic acid (of which 80% is glucuronic).
Calcium-replete human TSP was isolated from the supernatants
of thrombin-activated platelets by affinity chromatography over
gelatin-Sepharose and heparin-Sepharose (Pharmacia, Piscat-
away, New Jersey, USA) followed by gel-filtration (Bio-Gel A
0.5 m; Biorad, Richmond, California, USA) 1271; a single peak
elutes under these conditions. This was concentrated and iodi-
nated as previously outlined [281. Briefly, 300 tl of 2 mg/ml TSP
in Tris-buffered saline (TBS) was added to an iodogen-coated
tube, then 100 to 200 tCi of carrier-free 1251 was added, and the
mixture incubated for 40 minutes at room temperature. To
remove unbound iodine, the iodinated material was passed over a
Sephadex G25 column that had been equilibrated with buffer
containing 0.1% gelatin. The specific activity of TSP obtained by
this procedure ranged from 0.1 to 0.3 Ci/g. Antibodies against
TSP (both monoclonal D-4.6 and a polyclonal) were the gifts of
Dr. V. Dixit, and their preparation and use has been described
[29J.
Isolation and culture of rat mesangial cells
Mesangial cells were isolated from four- to six-week-old, male
Sprague-Dawley rats by standard methods [11, 12]. In brief, rats
were anesthetized with chioral hydrate (350 mg/kg), their aortas
caniiulated and the kidneys perfused with sterile phosphate
buffered saline (PBS) before removal. Glomeruli were separated
from tubules by differential sieving with metal sieves (about 90%
purity) and plated on plastic in RPMI-1640 medium enriched with
2 g/liter NaHCO5, 15 mvi N-2-hydroxyethylpiperazine-N'-2-eth-
anesulfonic acid (HEPES) buffer, 25 jg/ml regular insulin, 100
U/mI penicillin and 100 g/ml streptomycin, 600 mg/liter glu-
tamine, and 20% fetal calf serum (FCS). Cultures were kept in a
5% C02, humidified atmosphere at 37°C. After reaching conflu-
ence, the mesangial cells were trypsinized and subcultured [11]. In
order to diminish phenotypic alterations, cells were used only
between passages 2 and 6.
Identification of the cells as mesangial was based on several
criteria. By inverted-phase microscopy the cells were stellate or
spindle-like (depending on the degree of confluence); by electron
microscopy they showed peripherally distributed myosin bundles
and lysosomes with frequent phagolysosomes. By immunofluores-
cence microscopy [111, they were positive for alpha-smooth
muscle actin, myosin, desmin, Thy-i, and negative for factor VIII
and the macrophage marker ED-i. Their growth was not impaired
by D-valine-substituted media (with dialyzed serum) or by ami-
nonucleoside of puromycin (50 tgIml).
Assay of DNA synthesis
For thymidine uptake experiments, 50,000 cells were seeded in
individual wells of 24-well plates (diameter 15.5 mm) in 1 ml
complete medium (20% FCS). When the attached cells reached
50% confluence, they were synchronized in G0 by washing them
twice with 0.5 ml Hank's balanced salt solution (HBSS) and
placing them in 1 ml serum-free medium (RPMI-1640 with
NaHCO3, HEPES, insulin, penicillin, streptomycin, and glu-
tamine, as described above, plus 1 mg/mI bovine serum albumin,
and 5 .tg/ml transferrin). After synchronization the cells were
placed in fresh serum-free medium in the presence of the
appropriate agents for varying times. PDGF and EGF were
replenished every 24 hours to maintain their mitogenic activity
throughout the experiment; this was critical for the 48 hour
incubations since it is known that their mitogenic effects are
maximal by 16 hours and rapidly decrease after 24 hours [30].
Cells in serum-free medium alone served as the negative controls,
whereas cells in 20% serum were the positive controls. In general,
the positive controls give a response between 5 and 10 times that
of the negative controls. 3H-TdR (81.3 Ci/mmol, 0.5 MCi/well) was
added at the beginning of the incubation in the 28 hour experi-
ments, and for the last 24 hours in 48 hour experiments. The
incubations were terminated by placing the plates on ice. The cells
were then washed twice with HBSS, incubated with 500 d 10%
trichioroacetic acid (TCA) at 4°C for 20 minutes, washed twice
with HBSS, and solubilized in 250 pA 1 N NaOH at 37°C for 30
minutes. After neutralizing the pH with equal amount of 1 N HC1,
the cell lysate was mixed with scintillation fluid and counted in a
scintillation counter.
Assays of lactic dehydrogenase (LDH) release and cell counts
A kit based on conversion of pyruvate to lactate was used
according to the instructions of the manufacturer. Cells in log-
growth phase in triplicate 35 mm dishes with serum-free medium
were incubated with 250 .tg/ml of heparan sulfate for 24 hours,
their supernatants were aspirated, centrifuged at 2,000 g X 10
minutes, and assayed for presence of LDH using a spectropho-
tometer at 340 nm. Negative controls consisted of cells in the
same medium in the absence of heparan sulfate, and positive
controls were cells under the same conditions as the negative
controls, which were lysed by repeated freezing and thawing.
After removal of supernatants and washes with HBSS, the cells
were incubated with trypsin 0.25%/EDTA 1 mivi X 10 minutes at
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37°C and counted in a hemocytometer in order to correct the
amount of LDH released for cell numbers.
Assays of growth factor and cytokine levels in supernatant fluids
Supernatants of cells in 24-well plates were used to measure
induction by thrombospondin of PDGF, EGF, TGF-f32, TNF-a,
IL-i 13, IL-6, and IL-8 production by mesangial cells. In these
experiments the medium used in the wells and to dilute the TSP
was colorless RPMI-1640 (that is, without phenol red) to avoid
interference with the ELISA assays. The supernatants were
centrifuged at 1200 g for five minutes and frozen at —20°C until
assayed. The Quantikine kits used are based on the quantitative
"sandwich" enzyme immunoassay technique. All incubations were
done at room temperature, unless otherwise stated. The second
antibody in each assay was conjugated with horseradish peroxi-
dase,
For PDGF we used 96-well polystyrene microtiter plates coated
with a murine monoclonal antibody against PDGF-AA. Fifty
microliters of assay diluent (provided in the kit) followed by 200
jtl of the appropriate sample were added to each well, mixed and
incubated for two hours. The wells were washed three times with
400 tl of wash buffer (provided), and 200 tl of a conjugated
polyclonal antibody to PDGF-BB added to each well and incu-
bated for two hours. The washes were repeated as before,
followed by addition of 200 tl per well of an equal-volume
mixture of stabilized H202 and tetramethyl benzidine (chromo-
gen) and incubation for 20 minutes. This reaction was stopped
with 50 d of a 2 N H2S04 solution. Optical density of each
solution was determined with a Dynatech (Chantilly, Virginia,
USA) MR 250 ELISA reader at 450 nm with wavelength correc-
tion set at 540 nm. The concentration of PDGF in each sample
was calculated by means of a standard curve generated using serial
dilutions of a human recombinant PDGF-AB solution supplied in
the kit. The sensitivity of the assay for PDGF-AB is 8.4 pg/mI in
culture media; it does not cross-react with other cytokines or
growth factors, and shows 10% cross-reactivity with PDGF-AA
and 2% with PDGF-BB.
For EGF Quantikine ELISA kit we used plates coated with
murine monoclonal antibody against EGF. Two hundred micro-
liters of each sample was added to the appropriate wells, incu-
bated for two hours, washed with buffer provided in the kit as
described before, and followed by addition of 200 tI of a con-
jugated polyclonal antibody against EGF. The plates were incu-
bated for one hour, the wells washed as before, the chromogen
mixture added, and further steps as described above. Recombi-
nant human EGF was used to construct the standard curve. The
sensitivity of this assay is 0.2 pg/ml EGF, and it does not
cross-react with other cytokines and growth factors.
The assays for TGF-f32, IL-1p, IL-6, IL-8, and TNF-a were also
done using Quantikine ELISA kits based on similar protocols. For
IL-6, the HS (high sensitivity) Quantikine assay was used (sensi-
tivity 0.064 pg/ml). For IL-8 100 il of assay diluent (provided) was
added to the wells followed by 100 d of the appropriate sample or
standard; both incubations (with the sample and with the conju-
gate) lasted two hours. For TNF-ci the incubations with the
sample and conjugate were done at 37°C for two hours.
Immunoblot for detection of TGF-p
The TSP preparation used in this study was examined for
presence of TGF-13 traces by means of an anti-TGF-f3 polyclonal
antibody kit purchased from R&D Systems. The samples of TSP
were subjected to SDS-PAGE on a gradient gel and then trans-
blotted and incubated for two hours with a polyclonal anti-TGF-f3
antibody prepared in rabbits, followed by incubation with biotin-
conjugated anti-rabbit IgG for one hour and then with alkaline
phosphatase-conjugated streptavidine, followed by color develop-
ment with the appropriate reagents supplied by the manufacturer.
Washes with Tween-containing buffer provided in the kit were
done between the various steps, as per kit instructions.
TSP binding assays
For binding experiments, cells were grown to confluence in
48-well plates, and washed three times with RPMI-1640. 0.5 ml of
blocking buffer (RPMI with 1% BSA) was added to each well and
incubated at 4°C on an orbital shaker for one hour. The wells were
washed with RPM! without BSA and 200 tl of ligand (diluted in
blocking buffer) added to each well, with incubation as before. At
the end of this incubation cells were washed three times with
RPM!, and solubilized by adding 0.5 ml of 1% SDS/well and
incubating at room temperature for 10 minutes, followed by
repeated pipeting up and down to assure that the cells were
solubilized. The cell lysate was transfered to tubes and radioac-
tivity counted in a LKB 1261 multigamma counter (LKB,
Bromma, Sweden). To examine competition by heparin, TSP was
incubated with 25 1itg/ml heparin at 4°C for 30 minutes before
addition to the wells. In each plate, two to three wells were
trypsinized with 0.1% trypsinhl M EDTA to obtain cell number per
well. Binding data were analyzed by computer-assisted nonlinear
curve fitting using the "Inplot" graphics program (GrapliPad
Software, San Diego, California, USA).
Statistics
The results were analyzed by one-way ANOVA for overall
significance. Tukey-B test and t-test were used to evaluate inter-
group differences [311. Differences were considered significant at
a level of P < 0.05. Results on thymidine uptake are expressed as
relative counts per minute (cpm) of 3H-TdR, considering the
negative controls as 100 cpm.
Results
Proliferative effects of TSP
TSP increased thymidine uptake by the mesangial cells in a
concentration-dependent manner. This effect was evident by 28
hours, when TSP at 10 ig/ml increased uptake by 13%, and by
49% at 20 sg/ml. The effect was more prominent at 48 hours,
when TSP at 5 g/ml increased thymidine uptake by 29%, 10
ig/ml by 52%, and 20 jtg/ml by 72% (Fig. 1). The dose range of
TSP used corresponds to 1 to 4 X 10—8 M.
Co-incubation of TSP with anti-PDGF neutralizing antibody
eliminated this effect. TSP 10 sg/ml increased uptake by 53%,
antibody alone at 25 ig/ml decreased basal uptake by 17%,
combinations of anti-PDGF at 1, 5, and 25 jtg/ml with TSP 10
tg/ml decreased uptake to 94 14, 103 14, and 70 4, re-
spectively (compared to negative controls of 100 5; P < 0.05).
Incubations with an irrelevant !gG antibody from goat (same host
as the anti-PDGF antibody) at 5 and 25 tg/ml did not affect
baseline uptake, and did not significantly alter TSP-induced
uptake (144 11 and 131 15, respectively; P = NS).
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Co-incubations of TSP 10 .tg/ml with 50 ig/ml monoclonal
antibody D-4.6 (against an epitope proximal to the C-terminal of
the TSP monomers) or with 50 .tg/ml of a rabbit polyclonal
anti-TSP failed to decrease the TSP effect (181 18 vs. 194 16
and 178 7); the antibodies, under these serum-free conditions,
had no effect on baseline uptake either. This experiment was
repeated with preincubation of the antibodies with TSP for 30
minutes at 37°C before addition onto the cells. Again, no change
was observed.
Interactions of TSP with growth factors
TSP had a biphasic effect on PDGF- and EGF-induced stimu-
lation of DNA synthesis. At 28 hours TSP 20 ig/ml slightly but
significantly inhibited the augmentation in thymidine uptake
caused by both these growth factors. Thus, PDGF 10— 10 M
increased 3H-TdR uptake to 432 23 (mean SEM, actual counts
adjusted to compare with negative controls of 100 cpm), whereas
in combination with TSP the uptake was 378 15 (N = 8 in both
experiments, P < 0.05); EGF 10_b M increased uptake to 209
12, but only to 165 7 in combination with TSP (N = 8, P <
0.05).
Contrary to these effects, 48 hour incubations of TSP at 5, 10,
and 20 j.tg/ml with EGF 10b0 to i0 M (thymidine labeling for
the last 24 hr) showed an additive effect for all dose combinations
(Fig. 1). TSP (10 g/ml) and also displayed an additive effect with
PDGF 10'° M (increase of thymidine uptake with PDGF by 20%,
P < 0.05; Fig. 2).
The TSP preparation used in this study was examined for
possible contamination by PDGF and by TGF-/3 using the Quan-
tikine ELISA and an immunoblot kit, respectively (both described
in Methods); it was found not to contain any traces of either
growth factor.
Interactions of TSP with heparin and heparan sulfate
The stimulatory effect of TSP on DNA synthesis was signifi-
cantly attenuated by heparin (100 .tglml), There was some batch
to batch variability in the effect of heparin, even though purchased
from the same source. In initial experiments, heparin decreased
DNA synthesis by mesangial cells by about 40%. This same batch
of heparin completely eliminated the effect of 20 jig/mI TSP on
DNA synthesis (down to the level of negative controls). In
subsequent experiments, the heparin used, even though itself
devoid of an independent antiproliferative effect, attenuated the
effect of 5 jig/ml TSP by 17% (P < 0.05), of 10 j.tg/ml TSP by 26%
(P < 0.05), and of 20 jig/ml TSP by 13% (NS) (Fig. 3).
In order to use a substance of more relevance to the glomerular
microenvironment, the effects of heparan sulfate were investi-
gated. In 28 hour as well as in 48 hour incubations, heparan sulfate
from bovine lung (fraction 1.3) [11] at 250 jig/ml completely
abrogated any proliferative effect of TSP (Fig. 4).
Even though in our previous experience [11] heparan sulfate
did not cause any damage to the mesangial cells in the concen-
trations used, we checked again for such possibility, since now the
experiments were done in the absence of serum. The release of
LDH by the cells treated with heparan sulfate was no different
than that of negative controls and in turn not significantly different
from background activity. This remained true even when results


















































Fig. 1. Effects of various doses of TSP alone and in combination with EGF
on 3H-TdR uptake by rat mesangial cells. In this experiment incubations
lasted for 48 hours, and EGF was not replenished at 24 hours. *D < 0.05
vs. negative controls, + P < 0.05 vs. TSP 10 .tg/ml alone, >< P < 0.05 vs.
TSP 20 .rg/ml alone, # P < 0.05 vs. EGF.
Fig. 2. Effects of TSP 10 g/ml in combination with PDGF or EGF on
3H-TdR uptake by rat mesangial cells. Fourty-eight hour incubations were
used with replenishment of PDGF and EGF every 24 hours. P < 0.05 vs.
negative controls, + P < 0.05 vs. TSP alone, # P < 0.05 for TSP + EGF






































































Induction of growth factor secretion by TSP
Incubations of the mesangial cells with TSP for 28 hours, (that
is, when the mitogenic effects of TSP were barely becoming
apparent), induced secretion of EGF and enhanced the secretion
of PDGF in the supernatant. The baseline production of EGF by
these cells under the serum-free conditions described in the
Methods section was negligible (<0.6 pg/mI, not different from
the blank of the standard curve). TSP at 10 g/ml and at 20 rg/ml
induced production of EGF in a dose-dependent manner (6.65
Fig. 5. Induction of EGF and PDGF-AB by TSP in 28 hour incubations.
Perpendicular scales are left for EGF, right for PDGF. p < 0.05 vs.
negative controls, +P < 0.05 induction with TSP 20 pg/mI vs. with TSP 10
pg/mi.
0.17 pg/mI and 13.16 0,22 pg/mI, respectively, mean SEM; Fig.
5).
The mesangial cells constitutively produced PDGF-AB (42 5
pg/mi) as described previously [8, 32]. However, in the presence of
TSP this amount was increased by up to twofold (Fig. 5).
The supernatants of these cells were also examined for secre-
tion of TGF-/32, IL-1f3, IL-6, IL-8 and TNF-cs. Baseline produc-
tion of IL-6 was about 0.1 pg/ml; this was not further induced by
TSP. The rest of the substances tested for were not produced by
either unstimulated or TSP-induced MC.
TSP receptors on rat mesangial cells
To determine the number and affinity of heparin-inhibitable
TSP receptors on mesangial cells grown in the presence of serum,
we conducted binding assays in the presence and abscence of 25
Lg/ml heparin. Heparin-specific binding (defined as the difference
between total binding and binding in the presence of heparin) was
saturable and had an apparent Kd of 80 29 n. This Kd
approximates well with the range of TSP doses used in these
experiments (5 to 20 .tg/ml or ito 4 x 10—8 M). The total number
of binding sites/cell was 3.8 1.8 x 106 (N = 4; Fig. 6).
Discussion
Proliferative effects of TSP on mesangial cells
TSP is produced by MC [24] and transcription of its mRNA is
stimulated by PDGF [25]. PDGF stimulates synthesis of TSP in
vascular smooth muscle cells [23]. In this study we have shown: (a)
that TSP causes a delayed onset, dose-dependent increase of
thymidine uptake by rat MC; (b) that it has an additive prolifer-
ative effect with EGF and PDGF; (c) that it induces production of
EGF and augments constitutive synthesis of PDGF by these cells;
and (d) that its proliferative effect as well as its binding to the MC
is inhibitable by heparin and heparan sulfate.
Based on these observations, we propose the presence in MC of
an autocrine growth stimulatory system, in which TSP induces
EGF production and augments PDGF secretion, thus indirectly






Fig. 3. Inhibition by heparin of TSP-induced increase of 3H-TdR uptake by
rat mesangial cells. Fourty-eight hour incubations were used with various
doses of TSP. Symbols are: (•—) TSP; (U--s) TSP + 100 pg/mI
heparin. In this particular experiment, the batch of heparin used was itself










Fig. 4. Inhibition by heparan sulfate of the TSP-induced increase of 3H-TdR
uptake in rat mesangial cells. Twenty-eight and 48 hour incubations were
used. Data are mean SEM. Symbols are: (—)10 pg/mI TSP; (A--A)
250 .rg/ml HS; (V"-V) TSP + HS. *P < 0.05 vs. negative controls; also P
<0.05 for heparan sulfate vs. TSP, and for H.S. + TSP vs. TSP.
28 48













Fig. 6. Binding of '251-TSP to MC. (A) TSP-specific heparin-inhibitable
binding represents the difference between binding in the absence (total
binding) and presense (non-specific binding) of 25 jtg/ml of heparin.
Heparin-inhibitable binding represents about 92% of total binding. (B)
Scatchard plot of heparin-inhibitable binding.
PDGF in turn induces production of TSP by the MC, thus creating
an augmentation ioop. This autocrine proliferation loop is tightly
regulated by heparan sulfate, a component of the glomerular
microenvironment.
The dose-dependent effect of TSP on DNA synthesis by MC is
first detectable at 28 hours of incubation and is further increased
at 48 hours, unlike the proliferative action of PDGF and EGF that
is apparent by 16 hours [301. This delay suggests that the
proliferative effect is indirect, and occurs through secretion of
intermediary growth stimulating molecules. TSP had an additive
proliferative effect with EGF, seen only after 48 hours of incuba-
tion; at 28 hours the combined effect of TSP and EGF was even
less than the effect of EGF alone, These results are partly at
variance with those of Majack, Cook and Bornstein [22] on
smooth muscle cells, where a synergistic effect between TSP and
EGF was seen in 30 hour incubations. TSP also enhanced the
effects of PDGF in an additive manner. The same time pattern
was seen as with EGF, that is, the enhancing effect was observed
after 48 hours, whereas at 28 hours there was a slight inhibitory
effect on action of PDGF. The mechanism of this slight inhibitory
effect at 28 hours with both EGF and PDGF is not clear at this
time. It may be due to reversible sequestration of these growth
factors into the large TSP molecule [14], which may temporarily
impede access of the growth factors to the MC.
Incubations of TSP with a monoclonal antibody against a
fibrinogen-binding domain close to its carboxyterminus did not
impair the proliferative effect of TSP. The same was true with a
polyclonal TSP antibody (whose epitope specificities are not
known). This suggests that the epitopes for these antibodies are
not related to the proliferative effect, either directly or through
allosteric effects on the aminoterminal heparin binding domain.
The latter domain seems to be most important for the observed
proliferative effect of TSP, since heparan sulfate and heparin
Fig. 7. A scheme of the proposed hypothesis on the role of TSP in the
regulation of mesangial cell growth in conjunction with EGF, PDGF and
heparan sulfate. PDGF can also be derived from platelets and macro-
phages infiltrating the glomerulus. Induced EGF may be acting on
adjacent podocytes as well.
completely inhibit the TSP effect, and the TSP binding is com-
pletely inhibitable by heparin. Majack, Goodman and Dixit [29]
were able to partially inhibit the proliferation of vascular smooth
muscle cells in the presence of 5% serum by using such antibodies,
and they interpreted those results as implying that TSP present in
the medium was responsible for the percentage of the prolifera-
tive response that was inhibited by the antibodies. However, they
did not report specific inhibition of the effect of exogenous TSP by
these antibodies under serum-free conditions. The various effects
of TSP (chemotaxis, adhesion, proliferation, etc.) seem to be
coordinately mediated by multiple domains of its molecule, and
distinct effects are differently influenced by individual antibodies
or competing peptides [26, 32]; thus, the use of various anti-TSP
antibodies in different cell systems under different experimental
conditions may not lend itself well to studies on specificity of TSP
effects. The specificity of the TSP effects observed in our study is
strongly supported by the facts, (1) that the product used elutes as
a single peak, (2) is not contaminated with PDGF or TGF-13, and
(3) binds to a single class of receptors with a Kd practically within
the range of TSP concentrations used, and inhibitable by heparin,
which also inhibits the proliferative effect of TSP.
Effects of TSP on growth factor production
This report represents the first demonstration of induced
autocrine production of EGF by MC. As expected, MC did not
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by TSP, in a dose-dependent manner, to produce picomolar
amounts of this growth factor. We have found that this concen-
tration of EGF increases thymidine uptake by rat MC by about
30% (unpublished observations). Autocrine proliferative loops for
mesangial cells have so far been described only for PDGF [33],
IL-i [34], IL-6 [35] and TGF-f3 [36]. It is possible that this
induction of EGF is one mechanism through which TSP increases
DNA synthesis by MC. The fact that anti-PDGF antibody com-
pletely abrogated the response to TSP is consistent with the
finding by Silver, Jaffer and Abboud [8], that the mitogenic
response of MC to EGF is mediated through induction of
autocrine PDGF. It is also possible that EGF produced by the MC
under these conditions stimulates proliferation of other cells in
the glomerulus, such as podocytes.
TSP also increased production of PDGF-AB by the MC in a
dose-dependent manner up to twice the amount secreted under
baseline conditions (which corresponds to picomolar amounts).
PDGF is a known autocrine growth factor for mesangial cells [33].
Such enhancement of its production by TSP, together with the
abrogation of the TSP effect by the anti-PDGF antibody, suggest
that the promotion of MC growth by TSP is due to enhancement
of the autocrine PDGF system. The delayed onset of action of
TSP, which suggests the presence of an intermediate substance,
strengthens this proposition. In light of these findings, we believe
that the additive effects of TSP with EGF and PDGF are simply
the effects of the autocrine amounts of these growth factors
induced by TSP. We are currently expanding these observations to
other PDGF isomers, and investigating if TSP acts at a transcrip-
tional or a translational level to cause these effects on EGF and
PDGF production. It should be noted that these effects of TSP are
specific, since it does not induce other cytokines for which there is
evidence of autocrine loops in MC, for example, IL-i, IL-6 and
TGF-/3.
Possible additional mechanisms of the growth-stimulatory effect
of TSP could be, that TSP, by causing partial detachment of MC
from their substratum, makes them more readily responsive to
other proliferative stimuli [14], or that by binding growth factors
[37], while it is itself bound to matrix components, presents these
factors to the cells at high concentrations in a localized manner,
thus enhancing their action.
TSP binding and interaction with heparan sulfate
Mesangial cells exhibited a single class of binding sites, whose
number per cell and affinity were similar to those found in calf
pulmonary artery smooth muscle cells (Suchard SJ and Yabkowitz
R, unpublished observations). Binding to these sites had a Kd
similar to the range of TSP concentrations used in this study and
was inhibited by heparin. Heparin also inhibited the proliferative
effect of TSP indicating that these sites have a receptor function.
Experiments with heparan sulfate were undertaken, mainly be-
cause this glycosaminoglycan, in contrast to heparin, is a natural
component of the glomerular microenvironment, as it is secreted
by the podocytes and deposited in the glomerular basement
membrane and in the mesangial matrix [38, 39]. Heparan sulfate
caused a complete abrogation of the TSP effect on DNA synthesis
not just to the level of negative controls, but down to the level of
the antiproliferative effect of heparan sulfate itself. The negative
data from the LDH release assay rules out cell damage as an
explanation for these results. The completeness of the antagonism
by heparan sulfate suggests that the interaction between the two
substances is at the level of the TSP receptor, that is, that heparan
sulfate blocks access of TSP to its receptor, as is corroborated by
our finding that the TSP receptors on mesangial cells were
heparin-displaceable. It is also in agreement with information
from other cell systems, that one of the TSP receptors is a cell
membrane-associated heparan sulfate proteoglycan, and that hep-
arm inhibits interaction of the TSP molecule with this receptor by
substituting for the receptor on its specific binding site at the
N-terminals of the TSP constituent polypeptide chains [i4].
These findings do not exclude that, as with adhesion-, migra-
tion- and phagocytosis-promoting actions of TSP [20, 32, 40], its
proliferative effect depends on co-ordinate binding of the TSP
molecule on additional sites on the mesangial cells. An integrin
could be such a second binding site [16, 20], even though no
information currently exists about number and affinity of integrins
that bind TSP in MC or smooth muscle cells. Regardless of the
probable need for additional binding sites for the manifestation of
the proliferative effect of TSP, it is obvious from our work that the
heparin-binding domain is necessary for this effect.
Conclusion
Based on results presented herein, one can envision a positive
feedback loop promoting mesangial cell growth, where PDGF
stimulates production of TSP, which in turn enhances the produc-
tion of autocrine PDGF and other growth factors by these cells
further stimulating their proliferation. Under physiologic in vivo
conditions, such a loop would be under the tight suppressive
influence of heparan sulfate made available by the podocytes. In
pathologic conditions characterized by increased concentrations
of exogenous PDGF and TSP (from platelets and/or macrophages
entering the glomerulus), or by damage of the podocytes, this
balance between growth factors and TSP on one hand and
heparan sulfate on the other could be disturbed leading to
mesangial cell proliferation characteristic of many glomerular
diseases. Another potentially important feature of this proposed
model is that, by virtue of its tight binding to extracellular matrix,
TSP may serve to localize the proliferative responses to the
immediate vicinity of an inflammatory stimulus.
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